China Meheco Group(600056.SH): Clarithromycin Tablet Passes Generic Drug Consistency Evaluation.
China Medical (600056.SH) announced that its wholly-owned subsidiary, Tianfang Pharmaceutical Co., Ltd. (hereinafter referred to as "Tianfang Pharmaceutical"), recently received the approval notice for the supplementary application for the approval of clarithromycin tablets (hereinafter referred to as "the drug") issued by the National Medical Products Administration (hereinafter referred to as "NMPA"). The drug has passed the generic drug quality and efficacy consistency evaluation.
China Meheco Group (600056.SH) issued an announcement that its wholly-owned subsidiary, Tianfang Pharmaceutical Co., Ltd. (hereinafter referred to as "Tianfang Pharmaceutical"), recently received the approval notice for the supplementary drug application of clarithromycin tablets (hereinafter referred to as "the drug") issued by the National Medical Products Administration. The drug has passed the evaluation of generic drug quality and efficacy consistency.
Related Articles

Guosen: The final mindset of asset trend convergence.

Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.

Industrial: Hong Kong stock market sentiment index has reached the bottom area.
Guosen: The final mindset of asset trend convergence.

Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.

Industrial: Hong Kong stock market sentiment index has reached the bottom area.

RECOMMEND

Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026

Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026

Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026


